Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments. [electronic resource]
Producer: 20140818Description: e78856 p. digitalISSN:- 1932-6203
- Acute Disease
- Adalimumab
- Adult
- Aged
- Animals
- Anti-Inflammatory Agents -- administration & dosage
- Antibodies, Antineutrophil Cytoplasmic -- blood
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Cholestasis, Intrahepatic -- blood
- Cross Reactions
- Female
- Humans
- Immunoglobulin Fab Fragments -- immunology
- Immunologic Factors -- administration & dosage
- Male
- Mice
- Middle Aged
- Rituximab
- Vasculitis, Central Nervous System -- blood
No physical items for this record
Publication Type: Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.